Self-assembling peptides improve the stability of glucagon-like peptide-1 by forming a stable and sustained complex

Molecular Pharmaceutics

Volumn 10, Issue 9, 2013, Pages 3356-3365

  Li, Ying ^a   Shao, Mingxiang ^a   Zheng, Xuemin ^b   Kong, Weiling ^b   Zhang, Jianning ^a   Gong, Min ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

GLP 1; HbA1; insulin stimulation; long acting blood glucose clearance; self assembling peptides; sustained preparation

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; PEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG HALF LIFE; GEL FILTRATION; GLUCOSE TOLERANCE TEST; INSULIN RELEASE; MASS SPECTROMETRY; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; RAT;

ANIMALS; BLOOD GLUCOSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; MALE; MOLECULAR DYNAMICS SIMULATION; RATS; RATS, WISTAR; RATS, ZUCKER;

EID: 84883564684     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4001734     Document Type: Article

References (37)

1. Bailey, C. J. Insulin resistance and antidiabetic drugs Biochem. Pharmacol. 1999, 58 (10) 1511-20
2. Cho, L. W.; Jayagopal, V.; Kilpatrick, E. S.; Atkin, S. L. The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes Ann. Clin. Biochem. 2009, 46 (Part 3) 218-21
3. Stingl, H.; Roden, M. [Future targets in the treatment of type 2 diabetes] Wien. Klin. Wochenschr. 2004, 116 (7-8) 217-29
4. Tjokroprawiro, A. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer) Acta Med. Indones. 2006, 38 (3) 160-6
5. Zhang, Y.; Zhang, H.; Yao, X. G.; Shen, H.; Chen, J.; Li, C.; Chen, L.; Zheng, M.; Ye, J.; Hu, L.; Shen, X.; Jiang, H. (+)-Rutamarin as a dual inducer of Both GLUT4 translocation and expression efficiently ameliorates glucose homeostasis in insulin-resistant mice PLoS One 2012, 7 (2) e31811
6. Panina, G. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond Diabetes, Obes. Metab. 2007, 9 (Suppl. 1) 32-9
7. Komoroski, B.; Vachharajani, N.; Boulton, D.; Kornhauser, D.; Geraldes, M.; Li, L.; Pfister, M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin. Pharmacol. Ther. 2009, 85 (5) 520-6
8. Arulmozhi, D. K.; Portha, B. GLP-1 based therapy for type 2 diabetes Eur. J. Pharm. Sci. 2006, 28 (1-2) 96-108
9. Perry, T.; Greig, N. H. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease J. Alzheimer's Dis. 2002, 4 (6) 487-96
10. Gautier, J. F.; Choukem, S. P.; Girard, J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes Diabetes Metab. 2008, 34 (Suppl. 2) S65-72
11. Doyle, M. E.; Egan, J. M. Glucagon-like peptide-1 Recent Prog. Horm. Res. 2001, 56, 377-99
12. Briones, M.; Bajaj, M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus Expert Opin. Pharmacother. 2006, 7 (8) 1055-64
13. Drucker, D. J.; Dritselis, A.; Kirkpatrick, P. Liraglutide Nat. Rev. Drug Discovery 2010, 9 (4) 267-8
14. Giannoukakis, N. Exenatide. Amylin/Eli Lilly Curr. Opin. Invest. Drugs 2003, 4 (4) 459-65
15. Vilsboll, T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus Expert Opin. Invest. Drugs 2007, 16 (2) 231-7
16. Deacon, C. F. Potential of liraglutide in the treatment of patients with type 2 diabetes Vasc. Health Risk Manage. 2009, 5 (1) 199-211
17. Knudsen, L. B. Liraglutide: the therapeutic promise from animal models Int. J. Clin. Pract., Suppl. 2010, 64 (Suppl. 167) 4-11
18. Pujals, S.; Fernandez-Carneado, J.; Lopez-Iglesias, C.; Kogan, M. J.; Giralt, E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly Biochim. Biophys. Acta 2006, 1758 (3) 264-79
19. Zhang, S. Lipid-like self-assembling peptides Acc. Chem. Res. 2012, 45 (12) 2142-50
20. Deshayes, S.; Konate, K.; Rydstrom, A.; Crombez, L.; Godefroy, C.; Milhiet, P. E.; Thomas, A.; Brasseur, R.; Aldrian, G.; Heitz, F.; Munoz-Morris, M. A.; Devoisselle, J. M.; Divita, G. Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines Small 2012, 8 (14) 2184-8
21. Jeong, J. H.; Park, T. G.; Kim, S. H. Self-assembled and nanostructured siRNA delivery systems Pharm. Res. 2011, 28 (9) 2072-85
22. Yoshida, D.; Kim, K.; Takumi, I.; Yamaguchi, F.; Adachi, K.; Teramoto, A. A transfection method for short interfering RNA with the lipid-like self-assembling nanotube, A6K Med. Mol. Morphol. 2013, 46 (2) 86-91
23. Deshayes, S.; Morris, M.; Heitz, F.; Divita, G. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy Adv. Drug Delivery Rev. 2008, 60 (4-5) 537-47
24. Fernandez-Carneado, J.; Kogan, M. J.; Pujals, S.; Giralt, E. Amphipathic peptides and drug delivery Biopolymers 2004, 76 (2) 196-203
25. Cui, H.; Webber, M. J.; Stupp, S. I. Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials Biopolymers 2010, 94 (1) 1-18
26. Chugh, A.; Eudes, F.; Shim, Y. S. Cell-penetrating peptides: Nanocarrier for macromolecule delivery in living cells IUBMB Life 2010, 62 (3) 183-93
27. Li, Y.; Zheng, X.; Cao, Z.; Xu, W.; Zhang, J.; Gong, M. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin Int. J. Pharm. 2012, 434 (1-2) 209-214
28. Morris, M. C.; Depollier, J.; Mery, J.; Heitz, F.; Divita, G. A peptide carrier for the delivery of biologically active proteins into mammalian cells Nat. Biotechnol. 2001, 19 (12) 1173-6
29. Roy, R.; Biswas, T.; Hazra, T. K.; Roy, G.; Grabowski, D. T.; Izumi, T.; Srinivasan, G.; Mitra, S. Specific interaction of wild-type and truncated mouse N-methylpurine-DNA glycosylase with ethenoadenine-containing DNA Biochemistry 1998, 37 (2) 580-9
30. Sieminski, A. L.; Was, A. S.; Kim, G.; Gong, H.; Kamm, R. D. The stiffness of three-dimensional ionic self-assembling peptide gels affects the extent of capillary-like network formation Cell Biochem. Biophys. 2007, 49 (2) 73-83
31. Bais, M. V.; Kumar, S.; Tiwari, A. K.; Kataria, R. S.; Nagaleekar, V. K.; Shrivastava, S.; Chindera, K. Novel Rath peptide for intracellular delivery of protein and nucleic acids Biochem. Biophys. Res. Commun. 2008, 370 (1) 27-32
32. Chae, S. Y.; Choi, Y. G.; Son, S.; Jung, S. Y.; Lee, D. S.; Lee, K. C. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics J. Controlled Release 2010, 144 (1) 10-6
33. Chae, S. Y.; Jin, C. H.; Shin, J. H.; Son, S.; Kim, T. H.; Lee, S.; Youn, Y. S.; Byun, Y.; Lee, M. S.; Lee, K. C. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs J. Controlled Release 2010, 142 (2) 206-13
34. Jin, C. H.; Chae, S. Y.; Son, S.; Kim, T. H.; Um, K. A.; Youn, Y. S.; Lee, S.; Lee, K. C. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice J. Controlled Release 2009, 133 (3) 172-7
35. Gao, Z.; Bai, G.; Chen, J.; Zhang, Q.; Pan, P.; Bai, F.; Geng, P. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris Biosci., Biotechnol., Biochem. 2009, 73 (3) 688-94
36. Wang, Q.; Chen, K.; Liu, R.; Zhao, F.; Gupta, S.; Zhang, N.; Prud'homme, G. J. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist PLoS One 2010, 5 (9) e12734
37. Buse, J. B.; Rosenstock, J.; Sesti, G.; Schmidt, W. E.; Montanya, E.; Brett, J. H.; Zychma, M.; Blonde, L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009, 374 (9683) 39-47